Thank you both for your replies and info.
I live in Scotland, I believe the approval for new treatments is a different body here, not NICE, so I’m not sure what the situation is here re this treatment.
After doing a bit of googling I found this info.
Scottish Medicines Consortium (SMC):
The SMC, which approves treatments for use in NHS Scotland, has not yet approved cilta-cel for broader use.
I am not sure if NICE has an involvement in approval in Scotland, i.e. does it first have to go through NICE approval before being considered for approval in Scotland. This has not been the case for other treatments so I would assume it is not the case for Cilta-cel.
The link below would suggest that this is not the case, as one of the new treatments in the link was approved in Scotland before NICE approved it in England and Wales.
https://hcp.myeloma.org.uk/news/two-new-myeloma-treatments-for-scotland/
I was diagnosed in 2021 and have undergone initial chemo followed by a SCT 3 years ago in March 2022. I am currently in remission but unfortunately my condition was fairly advanced when first diagnosed, so I have quite a lot of initial damage. I had a follow up MRI this January as I was experiencing a lot of pain in my back. My initial MRI at time of diagnosis was 3 compressed vertebrae and significant damage to both my humerus bones, I had a pin put into my left humerus to prevent it shattering.
The MRI in January showed I now have 6 compressed vertebrae, one being at the bottom of my neck which has been giving me pain, and also damage to a rib. My Consultant has emphasised that this is previous damage which is coming home to roost despite Zoledronic Acid infusions and not new damage as Myeloma cells are not yet detectable in my bloods.
Anyway, discovering this new treatment has given me hope as it will have to many others. Hopefully this will he sorted out and introduced. However, the other new treatments look promising for extended remission, so we’re getting there.
Again, thanks for the info, much appreciated.